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thy. Dysfunction of one or more components of the mitral valve apparatus occurs in 39–74% and
affects almost all heart failure patients. Survival is decreased in subjects with more than mild mitral
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regurgitation is to slow or reverse ventricular remodelling, improve symptoms and functional class,
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Dilated cardiomyopathy (DCM) is usually associated with var-
iable degrees of functional mitral regurgitation with normal
valve morphology (Strauss et al., 1987; Sabbah and Goldstein,
1993; Koelling et al., 2002; Trichon and O’Connor, 2002;
Carabello, 2008). Mitral regurgitation (MR) imposes a haemo-
dynamic load on the left ventricle (LV), which, along with the
underlying cardiac injury, and in association with neurohor-
monal activation, results in negative ventricular remodelling,
which is deﬁned as alteration in the structure (dimensions,
mass, shape) and function of the heart (Cohn et al., 2000;
Dorn et al., 2003), which is characterized by progressive LV
dilatation and a change to a more spherical shape (Sabbah
and Goldstein, 1993; Tibayan et al., 2004). Remodelling ac-
counts for most instances of severe MR (Levine and Schwam-
menthal, 2005; Beeri et al., 2008; Carabello, 2008;Neilan et al.,
2008). Reversal of remodelling with both medical therapy and
an LV assist device is associated with marked improvements in
left ventricular function (LVF) in patients with advanced heart
failure (HF) (Birks et al., 2006). However, there are no curative
therapies speciﬁcally for the treatment of progressive LV dila-
tion, which is one of the strongest predictors of mortality (Pfef-
fer et al., 1992; Pieske, 2004).
To-date, clinical studies have several limitations: almost all
are retrospective, observational, and mostly single centre. They
all suffer from potential referral, selection, ascertainment, and
reporting biases and limited general application. Studies min-
gle patients with ischaemic and non-ischemic cardiomyopathy
with patients undergoing simultaneous coronary artery bypass
surgery.
Most studies have reported centre-speciﬁc techniques for
repair. While it is clear that the failing ventricle would beneﬁt
from relief of severe MR, unanswered questions remain
regarding appropriateness of patient selection, acceptable per-
ioperative mortality, and long-term survival beneﬁt. Does sur-
gery alter the natural course of HF? Does it reduce mortality?
When is the best time for surgery? How much does MR con-
tribute to symptoms and disease progression?
It is still unclear in the absence of randomized trials evalu-
ating MV surgery in patients with dilated cardiomyopathy and
symptomatic heart failure when to intervene surgically.
2. Mechanism of FMR
The MV in FMR is morphologically thought to be ‘‘normal’’.
However, some suggest that the MV in DCM is biochemicallydifferent from normal with extracellular matrix changes that
are inﬂuenced by the altered cardiac dimensions. This remod-
elling suggests that MR in patients with HF may not be
purely functional and that these valves are not ‘‘normal’’
(Grande-Allen et al., 2005). The MV apparatus is a complex
structure composed of the mitral annulus, mitral leaﬂets,
chordae tendinae, papillary muscles and the left ventricular
and left atrial walls. A competent MV needs well coordinated
function of all of these structures (Perloff and Roberts, 1972).
FMR mostly results from dysfunction of one or more of these
components. In DCM, ventricular dilatation causes MR
through annular dilation, an increase in the interpapillary
muscle distance, ampliﬁed leaﬂet tethering (elongation and
stretch on the chordae tendinae because of cardiac enlarge-
ment) causing MV tenting, and decreased closing forces from
muscle weakness and asynchrony of papillary muscle contrac-
tile timing (He et al., 1997; Yiu et al., 2000; Nielsen et al.,
2002; Jimenez et al., 2003; Karagiannis et al., 2003). The ﬁnal
common pathway is a failure of coaptation and FMR (Spoor
and Bolling, 2008). MR in these patients is primarily a func-
tion of distorted LV geometry rather than a primary valve
problem and results primarily from tethering of the MV leaf-
lets due to ventricular remodelling, speciﬁcally increased LV
dilation and sphericity (Levine and Schwammenthal, 2005).
It should be noted that contractile dysfunction alone in the
absence of ventricular dilation or increased sphericity does
not result in signiﬁcant MR (Gaasch and Meyer, 2008). From
a physiological point of view MR in these patients will lead to
LV overload and reduction of forward stroke volume. This
occurs initially in response to exercise and subsequently at
rest, which in turn activates systemic and local neurohor-
monal systems, and cytokines that worsen cardiac loading
conditions and promote negative LV remodelling and dys-
function ( Mann, 1999). This might create a vicious cycle
where FMR begets more FMR.
There are several predictors of FMR in DCM where MV
tenting and tethering length is the most powerful predictor
(Otsuji et al., 1997). Increased LV sphericity (Kono et al.,
1992; Sabbah et al., 1992) annular dilation and reduced closing
forces primarily ‘‘modify’’ tethering but are not the predomi-
nant mechanisms of MR (Levine and Schwammenthal,
2005). In the ACORN trial, LV diastolic dysfunction (LVDD)
was found to play a signiﬁcant role in the FMR development.
The major determinant of MR severity was the tenting area,
and this was best related to mitral annular area, which was
strongly associated with left atrial (LA) volume. In addition,
the LA volume index was highly correlated with LVDD. These
ﬁndings suggest that LA enlargement caused by advanced dia-
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augmenting mitral annular dilatation in DCM (Park et al.,
2009).
3. Prevalence and implication of FMR in HF
FMR is a signiﬁcant complication of end-stage cardiomyop-
athy and it may affect almost all heart failure patients as a
pre-terminal or terminal event. In a Mayo Clinic series of
558 patients with the New York Heart Association (NYHA)
class III–IV HF, 39% had moderate or greater MR (Star-
ling, 2007; Patel et al., 2004). Patients with signiﬁcant MR
had higher mortality (p= 0.03). Koelling et al. (2002) retro-
spectively reviewed 1421 patients with systolic dysfunction
and reported that signiﬁcant FMR is present in 49% of pa-
tients with HF, 20% of patients exhibited severe MR with a
consequent decrease in their 1- and 5-year survival rate
(59% and 35%, respectively). Patient survival at a mean fol-
low-up of 1 year varied inversely with MR grade (Koelling et
al., 2002; Levine and Schwammenthal, 2005). Nieminen et al.
evaluated 3580 patients hospitalized with acute heart failure
in 133 centres and found moderate or severe MR in 43% (
Nieminen et al., 2006). Robbins et al. (2003) reported that
45% of outpatients and 74% of hospitalized patients with
HF had echocardiographic evidence of moderate to severe
MR.
Despite similar LV dimensions, patients with MR had an
increased mortality compared to those without. In a Duke
University series, Trichon et al. (2003) examined a cohort of
2057 patients with symptomatic HF (NYHA II–IV functional
class) and noted 56.2% to have MR, 29.8% in the moderate–
severe range. Survival was decreased in subjects with more
than mild MR irrespective of the aetiology of HF. Survival
rates at 1, 3, and 5 years were signiﬁcantly lower in patients
with moderate to severe MR versus those with mild or no
MR (p< 0.001). MR was found to be an independent predic-
tor of mortality and is reportedly an indicator of poor progno-
sis in patients with DCM (William Abraham and Waldo, 2006;
Strauss et al., 1987; Blondheim et al., 1991; Conti and Mills,
1993; Otto, 2001; Koelling et al., 2002; Robbins et al., 2003;
Trichon et al., 2003; Fukuda et al., 2005). In a further study
of 130 patients awaiting transplantation, the 1-year survival
was only 46%.
Signiﬁcant independent predictors of death for these pa-
tients with idiopathic DCM were low forward stroke volumes,
with an EF of less than 25%, and MR (Stevenson et al., 1987).
Other predictors are episodes of heart failure, and increased
LV end-diastolic volume (Anguita et al., 1993). Most patients
with DCM die from heart failure despite improvements in
medical therapy. The 1-year survival was 25% in a study of
medically treated patients in NYHA class IV ( Rose et al.,
2001).
The question then is whether such patients have a worse
prognosis because of the MR or because their ventricles are
more intrinsically damaged to begin with. According to the
updated ACC/AHA guidelines for managing patients with
HF (Hunt, 2005), MR is a poor prognostic sign for patients
with end-stage cardiomyopathy. Yamano et al. (2008) studied
patients with FMR during exercise and concluded that FMR
was signiﬁcantly exacerbated during exercise, which was
strongly related to their exercise intolerance, thus, the clinicalimpact of FMR in patients with DCM could be more serious
than can be expected by its degree at rest.
Bursi et al. examined the independent prognostic role of
FMR and its impact across the severity of CHF in a large pop-
ulation of outpatients with systolic HF. Four hundred and
sixty-nine patients were followed-up for death and heart trans-
plant according to severity of their FMR on baseline echocar-
diography. The 5-year transplant-free survival was 82.7% in
patients with no or Grade I FMR, 64.4% in Grade II,
58.5% in Grade III, and 46.5% in Grade IV (p< 0.0001).
There was a strong association between FMR and the long-
term risk of death and heart transplant. The association be-
tween FMR and events was strong and independent in patients
with less severe symptoms and in those at a lower overall risk
based on a propensity score analysis, while it was not signiﬁ-
cant in patients with more advanced CHF or in the high-risk
subgroup. This study clariﬁes previous apparently discrepant
results by demonstrating that FMR is an independent determi-
nant of death and heart transplantation only in less severe
CHF and in patients with a lower risk proﬁle. This ﬁnding
indicates that FMR plays a major role in the early phase of
HF and should therefore be the focus of therapeutic strategies
attempting to reduce it (Bursi et al., 2010).
4. Treatment of FMR in HF
There are several methods to reduce MR, including optimal
medical therapy, treating arrhythmias, cardiac resynchroniza-
tion therapy, cardiac passive, restraint or constraint devices,
and MV surgery (Starling, 2007). Advances have been made
with medical therapy and cardiac resynchronization but,
despite such measures, outcomes remain poor in individuals
with advanced HF (Rose et al., 2001). Surgical correction of
MR is not performed frequently as a stand alone procedure
in patients whose primary problem is a dilated failing heart
( Enriquez-Sarano et al., 2008). Cardiac transplantation, the
ultimate therapy for end-stage HF, is plagued by the limited
supply of donor hearts and the need for lifelong immunosup-
pression (Hosenpud et al., 2000; Miller et al., 2007; Esmore
et al., 2008). It was once thought that patients with LV
dysfunction and MR would suffer if their MV were made com-
petent as they would lose the pop-off effect of MR (reversal of
blood ﬂow was somehow beneﬁcial to LV function). The high
mortality in earlier studies appears mainly related to loss of LV
function by disruption of the sub-valvular apparatus because
valve replacement (rather than repair) was mostly performed.
The ‘‘pop-off’’ effect has been disproved and MV repair has
been found not to add to surgical mortality (Bolling, 2002).
MV repair (MVR), speciﬁcally mitral annuloplasty (MVA),
has been proposed for selected patients with FMR due to sys-
tolic HF, although supportive data are limited to observational
studies. Reduction of MR by MVA using partial or complete
annuloplasty rings is accomplished by reducing the septal–
lateral diameter of the annulus, with resulting improved leaﬂet
coaptation.
Bolling and colleagues 1995 demonstrated that this ap-
proach was feasible and could be conducted with reasonably
low morbidity. MVA using an undersized ring effectively
corrects MR in HF patient and can safely be performed in
patients even with the most compromised ventricles with an
operative mortality of <5% and 75% one year survival
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(2000) at the Cleveland Clinic, demonstrated an operative
mortality of 2.3% in 44 patients with severe MR and severe
LV dysfunction (EF < 35%) who underwent isolated MVR
or replacement demonstrated reverse ventricular remodelling,
improvement in NYHA functional class, and freedom from
readmission for HF of 88%, 82%, and 72% at 1, 2, and
5 years, respectively, but the majority of the patients in this co-
hort have organic MR. These patients were also able to toler-
ate higher doses of medications after repair with 1, 2 and 5-
year survival rates of 89%, 86% and 67%, respectively. MV
surgery offered symptomatic improvement and survival beneﬁt
in patients with severe LVD and MR and more use of this sur-
gery for FMR in DCM patients is warranted. As surgeons
gained more experience and expertise with MVR, the surgical
mortality improved substantially and the use of MVR for pa-
tients with DCM has become a reasonable option (Calaﬁore et
al., 2001). In selected patients, MV surgery, speciﬁcally MVA,
in which the sub-valvular apparatus is left intact can lead to re-
duced ventricular size, improved LVEF and HF symptoms
(Rothenburger et al., 2002; Carabello, 2004), and high-risk
MV surgery may be an alternative to heart transplantation
in some patients, however, this is not documented or sup-
ported by current practice guidelines. Bolling (2002) reported
in a landmark study from the University of Michigan in 140
patients with NYHA class III–IV and an EF < 25% who
underwent a downsized MVA with an operative mortality of
5% that the 1- and 2-year actuarial survival was 80% and
70%, respectively (Bolling, 2002). This indicates that MVA is
the current standard means of correcting MR associated with
end-stage DCM (Bolling et al., 1995; Bach and Bolling, 1996;
Bolling, 2002; Bax et al., 2004) and has been demonstrated to
improve end-diastolic volume, LV performance, HF symptoms
and exercise tolerance (Bolling et al., 1998; Chen et al., 1998;
Konertz et al., 2001; Badhwar and Bolling, 2002a,b; Gummert
et al., 2003; Romano and Bolling, 2003, 2004; Mehra and Grif-
ﬁth, 2005; Jessup et al., 2006). Szalay et al. (2003) compared a
posterior MV annuloplasty using a ﬂexible ring in 121 patients
with signiﬁcant FMR, ischaemic (75%) and non-ischaemic
(25%) with an EF 6 30% and found early mortality of
6.6%, which was equal for both groups and the improvement
in NYHA class was equal between groups after 1 year. Hence,
MVA is effective in patients with severely depressed LVF and
has acceptable operative mortality and mid-term results which
are superior to medical treatment alone and comparable to
cardiac transplantation. Haan et al. in 2004 studied 727 pa-
tients (LVEF 6 0.30) who underwent MV surgery between
1998 and 2001 and found mortality was less than 2% for mitral
MV repair (Haan et al., 2004;Gammie et al., 2007). Similar re-
sults were shown by the Mayo Clinic and Cleveland Clinic
teams (Mahon et al., 2004; Ngaage and Schaff, 2004). Wu et
al. performed a propensity analysis to compare MVA with
medical therapy in patients with severe MR and advanced
HF who underwent MVR (undersized ring) and a matched
control group treated medically at the University of Michigan
between 1995 and 2002 where they demonstrated 4.8% 30-day
mortality with no clearly demonstrable mortality beneﬁt con-
ferred by MVA for signiﬁcant MR with severe LV dysfunction
or in the combined end-point of death, implantation of an
LVAD, or urgent heart transplantation (Wu et al., 2005). Astudy of 289 patients with an EF 6 30% and FMR compared
ﬂexible and non-ﬂexible undersized complete mitral annulo-
plasty rings which showed an operative mortality of 5% and
less recurrence of MR with rigid rings (9.5% versus 2.5%),
while in a 1–5-year survival, improvement of EF and NYHA
class are comparable to others (Chen et al., 1998; Bishay et
al., 2000;Bitran et al., 2001;Calaﬁore et al., 2001;Radovanovic
et al., 2002; Spoor et al., 2006). THE RESTORE Group pro-
posed a new surgical approach that consists of implantation of
a mitral prosthesis that is smaller than the annulus with pres-
ervation and traction of the papillary muscles to reduce sphe-
ricity of the LV in end-stage cardiomyopathy. One hundred
and sixteen patients with DCM underwent this procedure with
the following aetiologic factors: ischaemic (68), idiopathic (43),
Chagas disease (3), viral (1), and post-partum (1). All patients
were in an end-stage phase requiring >2 hospital admissions
over the past 3 months, despite receiving optimal medical ther-
apy. They reported 16.3% hospital mortality and a relatively
ﬂat late survival curve with evidence of improved clinical sta-
tus, better echocardiographic parameters, and reduction in
ventricular sphericity ( Buffolo et al., 2006). Recently, Geidel
et al. reported that the early and late results of restrictive
MVA in patients with chronic MR and advanced cardiomyop-
athy 3.3% 30-day mortality and 91% 12 months survival with
no postoperative recurrence of signiﬁcant MR (Geidel et al.,
2008). Similarly, data from Germany showed 7.5% operative
mortality and no differences in survival after MV repair or
replacement indicating that high risk MV surgery in patients
with cardiomyopathy and FMR offers a real mid-term alterna-
tive method of treatment for patients with drug refractory
heart failure with similar survival in comparison to heart trans-
plantation (Rukosujew et al., 2009). The most compelling data
for the safety and efﬁcacy of mitral valve repair for FMR
comes from the MV surgery arm of the prospective Acorn trial
(CorCap Cardiac Support Device, a prospective, randomized,
multi-centre trial). The Acorn device is a knitted polyester sock
that is drawn up and anchored over the ventricles in order to
limit left ventricular dilation and remodelling and improve
LVEF. Preliminary data suggest that the device produces an
improvement in HF symptoms, EF, left ventricular end-dia-
stolic dimension, and quality of life (Konertz et al., 2001; Shel-
ton et al., 2005). The Acorn trial, showed a 98.4% 30-day
survival rate, 2.1% repeat re-operation, and 85.2% 24 months
survival and signiﬁcant improvements in quality of life, exer-
cise performance, and NYHA class. Furthermore, MV opera-
tions lead to improvement in LV volumes, mass, and shape.
All consistent with reverse remodelling with considerable
safety and efﬁcacy ( Acker et al., 2006; Grossi and Crooke,
2006; Mann et al., 2007). As a result, the improvement in
LV structure and clinical function, along with a very low
mortality rate, justiﬁes strong consideration for offering MV
surgery to heart failure patients who are on an optimal medical
regimen. The outcomes do, however, support the hypothesis
that patients with cardiomyopathy beneﬁt from the surgical
correction of the FMR. The results of this study add to a
growing experience of clinical improvement with mitral valve
repair (Bolling et al., 1998). Unfortunately, there is still
considerable scepticism about the safety and efﬁcacy of mitral
valve surgery in patients with heart failure. The ACC/AHA
guidelines published in 2005 stated that ‘‘surgical treatment
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remodelling’’ and ‘‘it is possible that MVR for FMR reduces
symptoms and improves exercise tolerance but conclusive
data to support this hypothesis do not exist’’ ( Hunt et al.,
2005).
5. Percutaneous therapies
The potential for mechanical relief of MR without surgery has
ignited much interest. There are two primary approaches to
treating MR percutaneously: performance of an edge-to edge
(Alﬁeri) repair with a clip or a suture which opposes the cen-
tres of the two mitral leaﬂets producing a double-barrel open-
ing and reducing or eliminating MR while avoiding mitral
stenosis (Webb et al., 2006), and insertion of a device in the
coronary sinus to mimic the effects of a surgically-placed
annuloplasty ring (Block, 2005; Feldman et al., 2005).
By inserting devices into the coronary sinus that mechani-
cally alter its shape, the shape of the annulus is also altered,
in turn helping to restore MV competence (Dubreuil et al.,
2007; Gazoni et al., 2007). Early experience shows that these
devices can be effective. However, there are several possible
limitations to procedure. Firstly, the percutaneous techniques
will need to be as efﬁcacious, or nearly as efﬁcacious, as tradi-
tional MVR surgery. Although early results may be very good
for the percutaneous devices, their durability will need to be
closely followed. Edge-to-edge procedures do not incorporate
an MVA, an important determinant of durability in the Alﬁeri
MVR technique (Maisano et al., 2003). Coronary sinus-based
procedures do not account for the fact that the coronary sinus
has no anatomical connections to the mitral annulus, which is
in fact an intra-atrial structure, which may result in continued
annular dilation and recurrent MR over time (Singh and Bor-
ger, 2005). Secondly, percutaneous MVR should not preclude
the subsequent possibility of open surgical repair. Although
conventional MVR early after failed percutaneous techniques
has already been performed in several patients worldwide, it
will be important to determine whether MVR surgery is still
possible many months after a percutaneous procedure, when
scar tissue and adhesions have formed. Thirdly, the risk in tra-
ditional MVR is very low. Several large, single-institution ser-
ies (Bech-Hanssen et al., 2003; David et al., 2003; Matsumura
et al., 2003; Enriquez-Sarano et al., 2005) have reported very
low rates of operative mortality and morbidity in patients with
non-ischaemic MR. The bar has therefore been set very high
for percutaneous MV procedures. EVEREST (Endovascular
Valve Edge-to-Edge Repair Study) phase 1 clinical trial
(EVEREST I) (Feldman et al., 2005), was successfully com-
pleted after enrolment of 55 patients, demonstrating feasibility
and initial safety of the device with a reduction in MR in a sig-
niﬁcant proportion of patients. EVEREST II, aimed to evalu-
ate treatment with the percutaneous MitraClip device
compared with conventional MV surgery among patients with
severe MR and an EF > 25% who were candidates for MV
surgery; major adverse events at 30 days occurred in 15% of
the mitral clip group versus 48% of the control group
(p< 0.01 for superiority). Clinical success rate at 12 months
was 67% versus 74% (p= 0.05 for non-inferiority), respec-
tively (Feldman et al., 2009), and 2 years result reported mea-
surable improvement in LV volume and functional class
(Feldman et al., 2011). At 1 year, the MitraClip device demon-strated meaningful clinical beneﬁts for patients with signiﬁcant
MR including improvements in heart function, quality of life,
normal physical activity, and a decrease in cardiac symptoms.
In the primary effectiveness endpoint (freedom from death,
surgery for MV dysfunction, and >2+ MR at 12 months),
the MitraClip device was non-inferior to surgery at 1 year
(clinical success rate of 72.4% for MitraClip patients with suc-
cessful initial treatment compared to a clinical success rate of
87.8% for surgery patients). With 95% conﬁdence, the clinical
success rate of the MitraClip device falls within 25.4% of the
clinical success rate of the surgical control. In the per-protocol
group, 82% achieved 2+ or less mitral regurgitation versus
97% in the control group. NYHA class I or II at follow-up
was 98% in the clip group versus 88% in the control group.
Among patients with severe mitral regurgitation, repair with
a percutaneous mitral valve clip was feasible. This therapy
demonstrated improved safety at 30 days compared with sur-
gery, largely by reducing the need for blood transfusion. The
mitral valve clip was also non-inferior for effectiveness at
12 months. If the clip implantation proves to be feasible in
high-risk and HF patients with severe LV dysfunction, even
in those who do not match EVEREST or high-risk registry cri-
teria because of low LVEF or large dimensions and, eventu-
ally, in patients that are not responding to cardiac
resynchronization therapy, it could help to solve an important
clinical problem. At the moment, the MitraClip device therapy
appears a promising treatment option in patients with a clear
indication for MVR. It also seems appropriate for heart failure
patients with severe LV dysfunction, secondary functional
MR, and a substantially dilated ventricle. The current Euro-
pean Society of Cardiology’s guidelines recommend MV sur-
gery in patients with HF whenever they have to get re-
vascularized and only in selected patients with severe FMR
and severely depressed LV function, who remain symptomatic
despite optimal medical therapy (IIb, level C, recommenda-
tion) (Vahanian et al., 2007). It seems that elective surgical
procedures for FMR are mainly necessitated by the heavy
symptomatic burden of these patients. Thus, lacking a clear
indication for surgical repair in high-risk surgical candidates,
the MitraClip therapy might be an attractive, less invasive op-
tion for these patients with a major unmet clinical need.
6. Recurrence of FMR
Recurrent FMR is often explained away as being the result of
a ‘‘ventricular problem’’. Then why do some patients with
FMR manifest a beneﬁt from alleviating their MR. We are
faced with the question of whether the lack of beneﬁt purely
is the result of recurrence or is the recurrence of signiﬁcant
MR; a marker for a ventricle that has passed the point of no
return. In FMR, previous reports document 17–29% preva-
lence of recurrent MR early or late postoperatively (Tahta
et al., 2002; Spoor et al., 2006). However, the surgical ap-
proach in these series either used predominantly ﬂexible or
partial rings (Matsunaga et al., 2004; McGee et al., 2004;
Kuwahara et al., 2006). In the more recent CorCap study
(Acker et al., 2006) in which surgeons performed mitral valve
annuloplasty with predominantly undersized rigid complete
annuloplasty rings, recurrent MR was reassuringly uncommon
with only 4% experiencing signiﬁcant MR at 18-month follow-
up. Several factors have been described to account for recur-
130 H.S. Al-Amri et al.rent MR along with further LV remodelling and progressive
LV failure. Recurrent MR is often due to progressive lateral
displacement of the papillary muscles and attendant chordal
tethering, severe displacement of the anterior muscle may be
predictive of recurrence (Tahta et al., 2002). The data from
the University of Michigan identiﬁed the use of ﬂexible rings
as a risk factor for recurrent MR (Miller, 2001; Spoor et al.,
2006). Roshanali et al. (2007) pointed at an interpapillary mus-
cle distance of >20 mm as a risk factor for recurrent MR after
repair. Calaﬁore et al. considered tent height, deﬁned as the
distance between the mitral annulus and point of leaﬂet coap-
tation, >10 mm as a risk factor for failure after annuloplasty
for IMR (Calaﬁore et al., 2004). The coaptation depth (CD)
importance in FMR recurrence was debated where the isolated
undersized mitral annuloplasty improved clinical symptoms
and FMR in non-ischaemic DCM, while the pre-operative
CD of 11 mm or more does not always predict recurrent MR
after isolated undersized mitral annuloplasty for functional
MR due to non-ischaemic DCM (Miura et al., 2008). The
occurrence of reverse LV remodelling is associated with longer
repair durability and a better clinical outcome compared to
those with persistence or progression of the remodelling pro-
cess (De Bonis et al., 2008). Lee et al. (2009) examined the
Acorn trial data for the mechanisms of recurrent MR after
MVR for non-ischaemic cardiomyopathy and found recurrent
MR was associated with greater distal mitral anterior leaﬂet
angle, greater coaptation depth and tenting area, larger LV
volumes, and poorer LVEF. Hence, the post-operative mitral
competence is highly dependent on distal anterior leaﬂet
mobility.
7. Why beneﬁt is so hard to ﬁnd?
A positive impact on the mortality of correcting functional
MR is not apparent from the existing clinical studies and
may reﬂect inadequacies of the studies (retrospective, under-
powered, poorly characterized patient subsets, absence of
prospective core-lab controlled data). Symptomatic relief
and functional improvement occurs in most patients
although the difference versus alternative therapies is not
dramatic in existing observational studies. Trials with ven-
tricular remodelling as a surrogate endpoint will not resolve
clinical effectiveness of mitral intervention. Although the
investigation of Wu et al. (2005) suggests that patients re-
ceive little beneﬁt from mitral valve annuloplasty, several
questions are raised: even if the MR is corrected, the under-
lying muscle disease will still exist. This fact must contribute
to worsened prognosis of secondary MR (Carabello, 2008).
Is this lack of beneﬁt because mitral valve surgery does not
work or because a different surgical approach is needed? Is
annuloplasty sufﬁcient?
Are sub-annular, three-dimensional repairs required? We
simply do not know. Well-designed, randomized controlled tri-
als are warranted to resolve these issues. The respective roles of
MV repair versus replacement in patients with advanced HF
continue to evolve. Compared with patients undergoing MV
replacement with chordal preservation, patients undergoing
MVR have lower peri-operative mortality but a higher failure
rate. Because most series to date have reported patients under-
going MV repair rather than replacement, the lack of demon-
strated mortality beneﬁt in MV surgery in advanced HF mayreﬂect, in part, the less durable relief of MR afforded by MV
repair rather than replacement. MR recurrence and operative
mortality, counterbalance the beneﬁt which is limited to spe-
ciﬁc patient subgroups that have not been predeﬁned in the
current data sets (aetiology, duration of MR, LVEF, func-
tional class, etc.).
8. Guidelines
The lack of proven, long-term beneﬁts of mitral valve repair
or replacement for FMR is reﬂected in published guidelines
from major societies. The 2005 ACC/AHA HF guidelines
note that the effectiveness of MVR or replacement for se-
vere secondary mitral regurgitation in refractory end stage
HF is not established (Hunt et al., 2009). The 2006 Heart
Failure Society of America (HFSA) practice guidelines note
that isolated MVR or replacement for severe FMR in the
presence of severe LV systolic dysfunction is not generally
recommended (Heart Failure Society of America, 2006).
The 2006 International Society for Heart and Lung Trans-
plantation (ISHLT) guidelines for cardiac transplant candi-
dates notes that isolated MVR (not associated with
revascularization or ventricular restoration) should not be
routinely performed in patients with advanced LV dysfunc-
tion and HF (Jessup et al., 2006). The current updated
ACC/AHA valve disease guidelines (Bonow et al., 2008) in-
clude an appropriately cautious, but generally supportive,
recommendation for consideration of MV surgery in patients
with advanced HF but only if MVR or MV replacement
with chordal sparing are options. The authors conclude that
‘‘. . .even though such a patient is likely to have persistent
LV dysfunction, surgery is likely to improve symptoms
and prevent further deterioration of LV function’’. The
ESC guidelines for the diagnosis and treatment of acute
and chronic HF 2008, surgery for FMR may be considered
in selected patients with severe FMR and severely depressed
LVF, who remain symptomatic despite optimal medical
therapy-class of recommendation IIb, level of evidence C
(Dickstein et al., 2008).
9. Conclusion
Given the unproven long-term mortality beneﬁt from MV sur-
gery, treatment of FMR should emphasize optimal medical
therapy of HF and, in appropriate patients, cardiac resynchro-
nization therapy. MV surgery with current annuloplasty tech-
niques in carefully selected patients with advanced heart failure
should be considered before end-organ dysfunction becomes
irreversible or right ventricular function becomes impaired,
as such conditions increase the risk of operative intervention
and impact on long-term outcomes. Taking in account the lim-
itations, MV surgery may result in signiﬁcant symptomatic and
reverse remodelling beneﬁt in patients with DCM and FMR,
along with survival beneﬁt comparable to cardiac
transplantation.
Finally, MV surgery in DCM is an attractive treatment
which may beneﬁt many symptomatic patients with DCM
and may be an alternative option to cardiac transplantation.
The percutaneous MVR, MitraClip therapy, might be an
attractive, less invasive option for these high risk patients. Its
role in FMR treatment is yet to be proved.
Surgical treatment of functional mitral regurgitation in dilated cardiomyopathy 13110. Future challenges
Given the heterogeneity of remodelling, it is unlikely that a
‘‘one size ﬁts all’’ option will evolve for the durable correction
of severe MR in patients with advanced HF. Surgeons and
interventional cardiologists will require a portfolio of options
for more targeted, individualized repair of the annulus, leaﬂets,
chordae, and the remodelled ventricle. Just as more elegant
measures of myocardial reserve, more elegant measures of
LV reverse remodelling may improve surgical outcome of se-
vere MR in patients with advanced HF. Future measures of re-
verse remodelling viability may aggregate biomarkers, novel
molecular imaging modalities, and genomic and proteomic as-
says of myocardial tissue. By echocardiography and MRI, pa-
tients with MR exhibit ﬂattening of the annulus due to a
reduction in the saddle-horn height. Such ﬂattening may in-
crease leaﬂet closing stress and contribute to MR. Standard
annuloplasty rings are planar and do not conform to the nor-
mal saddle-shaped MV annulus. Development of three-dimen-
sional annuloplasty rings with better conformation to the
saddle-shaped annulus may provide additional reduction in
leaﬂet closing stress and MR.
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